Dr Chris Hand, executive chairman of Abingdon Health, said: “We are delighted to announce revenue growth of over 30% and a move into adjusted EBITDA profitability in the second half of the year. “Abingdon Health is well-positioned to build on this momentum through our integrated, end-to-end service offering and our growing international footprint, particularly servicing clients in the US.” Abingdon Health has recorded a rise in revenues of more than 30 per cent. Abingdon Health said reader unit sales worth £500,000 originally scheduled for the second half were deferred to August at the customer’s request. The company also continued to invest in its Group businesses during the year, including Abingdon Analytical and the build-out of manufacturing capability at Abingdon Health USA.